Format

Send to

Choose Destination
J Cancer Res Clin Oncol. 2018 Sep;144(9):1835-1842. doi: 10.1007/s00432-018-2702-9. Epub 2018 Jul 12.

The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study.

Author information

1
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Shanghai, 200433, China.
2
Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
3
Department of Health Services Research & Administration, University of Nebraska Medical Center, Omaha, NE, USA.
4
Division of Neurocritical Care, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
5
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Shanghai, 200433, China. jgnwp@aliyun.com.
6
Department of Endocrinology and Metabolism, The Center of Thyroid Diseases, The Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Middle Yanchang Road, Shanghai, 200072, China. huangyueye19890603@163.com.

Abstract

PURPOSE:

This study aimed to investigate the prognostic value of different organs metastases in patients with non-small cell lung cancer (NSCLC) and its most common subtypes.

METHODS:

We identified 45,423 NSCLC cases (25,129 men and 20,294 women) between 2010 and 2013 with distant metastases, with complete clinical information obtained from the surveillance, epidemiology, and end results (SEER) database.

RESULTS:

Bone and liver were the most and the least common metastatic sites with rates of 37.1 and 16.8%, respectively. The mortality rates associated with bone, brain, liver, lung metastases, and multiorgan metastases (MOM) were 73.2, 72.7, 78.3, 65.4, and 77.5%, respectively. Kaplan-Meier analyses demonstrated that patients with MOM and liver metastasis had the worst survival. Compared with NSCLC cases with other organ metastasis, but without the four organs metastasis, hazard ratios (HRs) for lung, bone, brain, and liver metastases, and MOM were 0.906 (95% CI 0.866-0.947), 1.276 (95% CI 1.225-1.330), 1.318 (95% CI 1.260-1.379), 1.481 (95% CI 1.388-1.580), and 1.647 (95% CI 1.587-1.709), respectively. Similar results were obtained for adenocarcinoma (AD) cases.

CONCLUSIONS:

The mortality risk is highest with MOM and liver metastasis followed by bone, brain, other organ, and lung metastases in NSCLC and AD which is the most common variant for NSCLC. These results will be helpful for pre-treatment evaluation regarding the prognosis of NSCLC patients.

KEYWORDS:

Metastasis; Non-small cell lung cancer; Prognosis; SEER

PMID:
30003315
DOI:
10.1007/s00432-018-2702-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center